Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,924,356
  • Shares Outstanding, K 219,173
  • Annual Sales, $ 4,991 M
  • Annual Income, $ 2,404 M
  • 60-Month Beta 1.39
  • Price/Sales 5.01
  • Price/Cash Flow 9.77
  • Price/Book 2.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 2.26
  • Number of Estimates 10
  • High Estimate 2.72
  • Low Estimate 1.92
  • Prior Year 2.55
  • Growth Rate Est. (year over year) -11.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.91 +13.82%
on 08/21/20
120.81 -5.87%
on 09/15/20
+10.41 (+10.08%)
since 08/18/20
3-Month
99.91 +13.82%
on 08/21/20
120.81 -5.87%
on 09/15/20
-2.60 (-2.24%)
since 06/18/20
52-Week
72.67 +56.49%
on 03/16/20
121.50 -6.40%
on 06/01/20
+10.74 (+10.43%)
since 09/18/19

Most Recent Stories

More News
Apellis Submits Pegcetacoplan Applications to FDA and EMA

Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.

ALXN : 113.72 (-0.36%)
EBS : 100.59 (-1.02%)
TECH : 243.90 (-0.54%)
APLS : 32.61 (+2.19%)
Alexion & Caelum Begin Studies on CAEL-101 in AL Amyloidosis

Alexion (ALXN) and partner Caelum Biosciences begin phase III studies on CAEL-101 in AL amyloidosis.

ALXN : 113.72 (-0.36%)
ALNY : 132.26 (+0.95%)
IONS : 51.39 (+0.19%)
AKCA : 18.15 (+0.06%)
Monoclonal Antibody Therapy Market to Reach USD 350.10 Billion by 2027; Increasing Number of Regulatory Approvals Will Aid Growth, says Fortune Business Insights(TM)

The global monoclonal antibodies therapy market size is projected to reach USD 350.10 billion by the end of 2027. The increasing prevalence of severe diseases such as cancer will create several opportunities...

ALXN : 113.72 (-0.36%)
AMGN : 247.72 (-0.15%)
BMY : 59.27 (-0.22%)
DSNKY : 91.8100 (-3.79%)
MRK : 85.81 (+0.20%)
NVS : 90.94 (-0.03%)
Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

--- Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response -

ALXN : 113.72 (-0.36%)
FBIO : 4.78 (+6.46%)
Alexion to Discuss Key Pipeline Programs at Virtual Investor Day

Alexion Pharmaceuticals (Nasdaq:ALXN) a biotechnology company focused in rare disease development and commercialization, today announced that the company will host a Virtual Investor Day on Tuesday, October...

ALXN : 113.72 (-0.36%)
Watch for Alexion Pharm to Potentially Rebound After Falling 1.42% Yesterday

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $102.88 to a high of $109.97. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $108.11...

ALXN : 113.72 (-0.36%)
Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS - ECTRIMS Meeting

--- Data from 11 abstracts demonstrate Alexion's commitment to continuing to advance the understanding of the burden of NMOSD for patients and the efficacy and safety of SOLIRIS in real-world settings...

ALXN : 113.72 (-0.36%)
Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know

Alexion Pharmaceuticals (ALXN) closed at $112.97 in the latest trading session, marking a +1.3% move from the prior day.

ALXN : 113.72 (-0.36%)
Alexion to Present at Upcoming Virtual Investor Conferences

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the following upcoming investor conferences:

MS : 50.08 (-0.34%)
ALXN : 113.72 (-0.36%)
Alexion (ALXN) Catches Eye: Stock Jumps 6.8%

Alexion (ALXN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ALXN : 113.72 (-0.36%)
TECH : 243.90 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ALXN with:

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

2nd Resistance Point 117.73
1st Resistance Point 115.73
Last Price 113.72
1st Support Level 110.76
2nd Support Level 107.79

See More

52-Week High 121.50
Last Price 113.72
Fibonacci 61.8% 102.85
Fibonacci 50% 97.08
Fibonacci 38.2% 91.32
52-Week Low 72.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar